Squamous cell carcinoma of the skin: Difference between revisions

	Squamous cell carcinoma of the skin Microchapters
Home
Patient Info
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Squamous cell carcinoma of the skin from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT Scan
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Squamous cell carcinoma of the skin On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Squamous cell carcinoma of the skin All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Squamous cell carcinoma of the skin
CDC on Squamous cell carcinoma of the skin
Squamous cell carcinoma of the skin in the news
Blogs on Squamous cell carcinoma of the skin
Directions to Hospitals Treating Squamous cell carcinoma of the skin
Risk calculators and risk factors for Squamous cell carcinoma of the skin

Revision as of 11:35, 19 June 2012

For patient information click here

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]

@@ Line 43: / Line 43: @@
 *'''[[Primary Prevention]]'''
 *'''[[Secondary Prevention]]'''
-==Future and Investigational treatment strategies==
-In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began [[clinical trials]] with a [[melanocyte-stimulating hormone]] called [[melanotan]]  (known by the [[International Nonproprietary Name]] ''afamelanotide'', formerly CUV1647)<ref name="Clinuvel-INN">{{Cite web|url=http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf|title=World Health Organisation assigns CUV1647 generic name|accessdate=2008-06-17|publisher=Clinuvel|year=2008|format=[[Portable Document Format|PDF]]}}</ref> to provide [[photoprotection]] for organ transplant patients against squamous cell carcinoma of the skin and [[actinic keratosis]].<ref name="Clinuvel">[http://www.clinuvel.com/en/faqs/ Clinuvel » Investors » FAQs<!-- Bot generated title -->]</ref><ref name="PharmaAsia">[http://www.pharmaasia.com/article-6618-clinuvelsdrugbeginsglobalphaseiiskincancertrials-Asia.html PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials]</ref>
-[[Cetuximab]] a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.
 ==References==